사람의 고양이 알레르기 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the cat allergy in humans market size is projected to expand from USD 6.45 billion in 2025 and USD 6.94 billion in 2026 to USD 10.78 billion by 2031, registering a CAGR of 9.22% between 2026 to 2031.

This report is Segmented by Product Type (Antihistamines, Corticosteroids, Allergen-Blocking Monoclonal Antibodies, Immunotherapy, Others), Route of Administration (Oral, Intranasal, Ophthalmic, Subcutaneous, Others), Prescription Status (OTC, Rx), Distribution Channel (Hospital, Retail, Online Pharmacy), and Geography (North America, Europe, and More). Market Forecasts are Provided in Terms of Value (USD).

Global Cat Allergy In Humans Market Trends and Insights

Rising Prevalence And Sensitization To Cat Allergens Among Allergic Rhinitis/Asthma Patients

Clinical studies in large urban cohorts document a steady rise in cat-dander sensitization that coincides with extended indoor exposure and lifestyle patterns that keep people and pets together in smaller living spaces. In central China, the share of allergic rhinitis patients with cat sensitization climbed across a six-year period, highlighting a clear need for therapy pathways that can offer durable control beyond short-term symptomatic relief. Pediatric and adolescent cohorts show a delayed peak for cat dander compared with dust mite, which suggests that cumulative environmental exposure and behavioral shifts, rather than early innate susceptibility, shape timing and severity.

These patterns broaden the base of candidates for immunotherapy and for supportive measures such as component-informed counseling that help align treatment with the specific allergen profile. They also sustain demand across multiple access points because patients often begin with OTC antihistamines and later escalate to prescription therapies or immunotherapy when symptoms persist despite self-management. As a result, the cat allergy in humans market continues to add patients across both symptomatic and disease-modifying care streams, reinforcing a durable growth outlook

Growing Pet Cat Ownership And Indoor Cohabitation Increasing Exposure Intensity

Pet-cat ownership in the United States rose quickly in 2024, lifting cat-owning households to 49 million and increasing the number of people who experience direct and frequent exposure to Fel d 1 indoors. The United Kingdom maintained a large cat population as well, and a quarter of households reported owning cats, confirming cross-market patterns that keep the allergen present in living spaces for long periods. These exposure trends feed demand for front-line OTC options that provide quick relief, followed by physician-directed regimens for persistent symptoms that fail to resolve on oral antihistamines alone. Allergen persistence within homes also supports interest in environmental and source-reduction strategies that can be paired with drug therapy to lower overall symptom burden during high-exposure periods. Providers apply this context to recommend integrated plans combining medication, immunotherapy when indicated, and everyday mitigation steps that match patient preference and risk tolerance. This ecosystem supports a balanced and growing cat allergy in humans market that serves a broad population across age groups and severity profiles.

No FDA-Approved SLIT Tablets For Cat, And SLIT Drops Not FDA-Approved In The U.S.

Sublingual tablets are FDA approved for grasses, short ragweed, and dust mite, but no cat dander tablet is licensed and liquid drops for cat remain off-label in the United States. This limits broad reimbursement and pushes many patients who prefer home administration toward SCIT or cash-pay sublingual drops prescribed in select practices that accept off-label use. Europe has demonstrated the process integrity for pediatric tablet expansion in other allergens, as seen in the 2024 approval of ACARIZAX for children, which shows that tablet platforms can progress when sponsors invest in the necessary dossiers and trials even if cat tablets are not yet available. Until a sponsor completes a cat-specific tablet program, the gap will continue to slow convenience-driven adoption in the United States relative to tablet-established allergens. This has a practical effect on channel dynamics because clinic-centered SCIT remains the most reimbursable pathway while sublingual drops scale more readily where national authorities already accept cat SLIT as standard of care. As a result, the cat allergy in humans market in the United States continues to rely on clinic-based models despite growing patient interest in home-use options.

Other drivers and restraints analyzed in the detailed report include:

1. Demonstrated Disease-Modifying Benefit And Physician Confidence In SCIT For Animal Dander
2. Emerging biologics enlarging addressable pool
3. SCIT Safety/Logistics Burden Limits Uptake And Adherence

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Antihistamines accounted for 38.43% of 2025 volume and remain the default starting point for many patients because they offer rapid symptom relief and easy access through retail aisles without a physician visit. Their longevity in practice and multiple oral formats support adherence for mild to moderate cases and sustain broad reach among first-line users who value predictable dosing. Intranasal corticosteroids address persistent congestion and nasal inflammation when oral antihistamines underperform, expanding physician-directed choices for patients who require stronger local anti-inflammatory control.

Allergen-blocking monoclonal antibodies are projected to expand at an 11.87% CAGR through 2031 as sponsors progress confirmatory trials and define coverage strategies for launch. Their fit is clearest for patients who want fast relief without daily pills or clinic visits every month, while immunotherapy remains the choice for those seeking a disease-modifying course of care over several years with physician oversight. Source-control nutrition that neutralizes Fel d 1 at the cat, including IgY-based diets that showed meaningful reductions in active allergen on hair by week three, can complement both drug therapy and immunotherapy inside homes that prefer to retain pets. This product mix, spanning consumer retail, prescription channels, and specialty biologics, helps the cat allergy in humans market serve heterogenous patient needs while keeping options open as evidence and labeling evolve.

Oral formulations held 45.34% share in 2025 on the strength of second-generation antihistamines that people can use without clinic visits. Oral tablets and liquids meet consumer expectations for immediacy and predictability, supporting seasonal use and daily maintenance for milder phenotypes. Intranasal corticosteroids occupy a distinct role because they suppress nasal inflammation and congestion that oral agents often fail to resolve completely, which keeps the nasal route attractive when upper-airway symptoms dominate.

The cat allergy in humans market size for subcutaneous administration is projected to expand at a 9.87% CAGR over 2026-2031 as clinics continue to standardize SCIT pathways and as biologics target cohorts that want fewer visits with sustained relief. Biologic programs that offer three-month durability after a single subcutaneous dose may further validate the injection route for convenience-focused patients if efficacy and safety remain consistent in confirmatory studies.

Geography Analysis

North America held 42.44% in 2025 in the cat allergy in humans market, supported by a dense allergist network, established SCIT pathways, and consistent use of component-informed testing that improves patient selection and dosing decisions. Cat ownership surged by 23% in 2024 to reach 49 million U.S. households, which increased exposure among sensitized individuals and lifted demand across OTC and prescription therapies as well as specialty services. Regional innovation density adds momentum because Fel d 1-blocking monoclonal antibodies continue to generate positive results in late-stage studies, and sponsors have committed to registration-enabling trials in 2026.

Europe maintains a substantial footprint shaped by national formularies that support immunotherapy and by a long history of sublingual use across other allergens, even as there is no approved cat tablet. Recent pediatric tablet approvals in dust mite show that sponsor-led clinical programs can scale successfully once efficacy and safety are clear, which offers a template for future cat-specific filings if pursued. Real-world evidence from Spain confirms SCIT effectiveness in routine practice and supports allergists' confidence in depigmented, polymerized extracts as part of long-term care for appropriate patients.

Asia-Pacific is the fastest-growing region with an 11.95% forecast CAGR as urbanization, rising pet ownership, and increasing access to diagnostics and immunotherapy combine to expand treatment. In China, clinical cohorts show higher cat-dander sensitization in recent years, which supports the need for therapies and reinforces the role for component-resolved testing when prescribers consider multi-year plans. China's prior experience with standardized sublingual products for other respiratory allergens also provides a platform for future cat-specific pathways if sponsors dedicate programs and trials. As testing and therapy broaden across urban centers, patient flow into structured, component-informed care is expected to accelerate and reinforce the cat allergy in humans market trajectory.

1. Alcon
2. ALK-Abello A/S
3. Allergy Laboratories, Inc.
4. Amgen
5. AstraZeneca
6. Bausch + Lomb
7. Bayer
8. Church & Dwight
9. Glenmark Pharmaceuticals
10. Haleon
11. Hikma Pharmaceuticals
12. HollisterStier Allergy
13. Kenvue
14. Perrigo
15. Regeneron Pharmaceuticals
16. Sanofi
17. Stallergenes Greer
18. Teva Pharmaceutical Industries

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Prevalence and Sensitization to Cat Allergens Among Allergic Rhinitis/Asthma Patients
  • 4.2.2 Growing Pet Cat Ownership and Indoor Cohabitation Increasing Exposure Intensity
  • 4.2.3 Demonstrated Disease-Modifying Benefit and Physician Confidence in SCIT for Animal Dander
  • 4.2.4 Expansion of Treatment Options Across OTC, Rx, AIT and Emerging Biologics
  • 4.2.5 Allergen-Exposure Reduction Solutions Broadening Adjunct Management
  • 4.2.6 Emerging Biologics Enlarging Addressable Pool
• 4.3 Market Restraints
  • 4.3.1 No FDA-Approved SLIT Tablets for Cat
  • 4.3.2 SCIT Safety/Logistics Burden (In-Clinic Dosing, Anaphylaxis Risk) Limits Uptake
  • 4.3.3 Multi-Year Adherence Challenges and Discontinuations in AIT Reduce Outcomes
  • 4.3.4 Extract Variability and Product Standardization Differences Affect Consistency
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Antihistamines
  • 5.1.2 Corticosteroids
  • 5.1.3 Allergen-blocking Monoclonal Antibodies
  • 5.1.4 Immunotherapy
  • 5.1.5 Others (Nasal Decongestant, etc)
• 5.2 By Route of Administration
  • 5.2.1 Oral
  • 5.2.2 Intranasal
  • 5.2.3 Ophthalmic
  • 5.2.4 Subcutaneous
  • 5.2.5 Others
• 5.3 By Prescription Status
  • 5.3.1 Over-the-Counter (OTC)
  • 5.3.2 Prescription (Rx)
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacy
  • 5.4.2 Retail Pharmacy
  • 5.4.3 Online Pharmacy
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 Alcon
  • 6.3.2 ALK-Abello A/S
  • 6.3.3 Allergy Laboratories, Inc.
  • 6.3.4 Amgen
  • 6.3.5 AstraZeneca
  • 6.3.6 Bausch + Lomb
  • 6.3.7 Bayer AG
  • 6.3.8 Church & Dwight
  • 6.3.9 Glenmark
  • 6.3.10 Haleon
  • 6.3.11 Hikma Pharmaceuticals PLC
  • 6.3.12 HollisterStier Allergy
  • 6.3.13 Kenvue
  • 6.3.14 Perrigo
  • 6.3.15 Regeneron Pharmaceuticals Inc.
  • 6.3.16 Sanofi
  • 6.3.17 Stallergenes Greer
  • 6.3.18 Teva Pharmaceutical Industries Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment